A Multi-scale systems pharmacology approach to TB therapy

结核病治疗的多尺度系统药理学方法

基本信息

  • 批准号:
    9335957
  • 负责人:
  • 金额:
    $ 71.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-01 至 2020-08-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Tuberculosis (TB) is a pulmonary disease resulting from infection with Mycobacterium tuberculosis (Mtb). TB is treatable but requires multiple antibiotics taken for >6 months, and the emergence of drug resistant Mtb (MDR and XDR-TB) has strained our current small arsenal of effective TB drugs. The situation is desperate considering there are 9 million new cases of active TB every year. The pathological hallmarks of TB are granulomas, dense spherical collections of immune cells that serve to protect the host but also isolate and shelter the pathogen. Granulomas pose a two- fold challenge to TB treatment: granulomas present a physical barrier for antibiotic penetration, and bacterial subpopulations with diminished antibiotic susceptibility emerge within granulomas. These difficulties contribute to the challenge of devising new and more effective treatment strategies for TB: getting the right drugs at the right concentration to the right location to kill the appropiate bacterial subpopulation. Processes that participate in these dynamics act across scales ranging from molecular (e.g. drug diffusion), cellular (e.g. macrophage activation), tissue (e.g. granuloma formation), organs (e.g. blood delivery of antibiotics) up to the entire host. To elaborate mechanisms driving dynamics in this complex system and to answer this vital challenge, we propose a multi-scale systems pharmacology approach. We use multi-scale computational modeling to track drug distributions in granulomas and development of resistance. We identify a novel bridge between the scale of host lung granulomas to the entire host scale where the disease manifests, and we use new approaches to predict better treatment options. We partner this with state-of-the-art experimental methods for imaging drug distribution within granulomas from humans, non-human primates (NHP) and rabbits. We perform Virtual Clinical Trials and test our prediction of a specific regimen for an efficacy trial in NHP models o TB with human-like pathology. To tackle this challenging proposition, we propose to: (1) Determine the spatial and temporal distributions of TB antibiotics within granulomas, and predict the development of resistance; (2) Identify optimal antibiotic treatment regimens for TB using genetic algorithms to narrow the combinatorial design space of antibiotics (e.g. drug classes, dosing, schedule); (3) Perform virtual clinical trials at a population level to test treatment regimens we identify, and test the optimal regimen in the NHP system against a standard regimen. Our outstanding interdisciplinary team and unique approach will allow for rapid assessment of new strategies and ultimately reduce the number of TB deaths world-wide.
 描述(由申请人提供):结核病(TB)是由结核分枝杆菌(Mtb)感染引起的肺部疾病。结核病是可治疗的,但需要服用多种抗生素>6个月,耐药结核分枝杆菌(MDR和XDR-TB)的出现使我们目前的有效结核病药物库紧张。考虑到每年有900万新的活动性结核病病例,情况令人绝望。结核病的病理特征是肉芽肿,密集的球形免疫细胞集合,用于保护宿主,但也隔离和庇护病原体。肉芽肿对TB治疗提出了双重挑战:肉芽肿为抗生素渗透提供了物理屏障,并且在肉芽肿内出现了抗生素敏感性降低的细菌亚群。这些困难导致了设计新的和更有效的结核病治疗策略的挑战:将正确的药物以正确的浓度送到正确的位置,以杀死适当的细菌亚群。参与这些动力学的过程跨越范围从分子(例如药物扩散)、细胞(例如巨噬细胞活化)、组织(例如肉芽肿形成)、器官(例如抗生素的血液递送)到整个宿主的尺度起作用。为了详细说明在这个复杂的系统中驱动动力学的机制,并回答这个重要的挑战,我们提出了一个多尺度系统药理学方法。我们使用多尺度计算模型来跟踪药物在肉芽肿中的分布和耐药性的发展。我们确定了宿主肺肉芽肿规模与疾病表现的整个宿主规模之间的一个新的桥梁,我们使用新的方法来预测更好的治疗方案。我们将其与最先进的实验方法相结合,用于成像人类,非人灵长类动物(NHP)和兔子肉芽肿内的药物分布。我们进行虚拟临床试验,并在具有人类病理学的结核病NHP模型中测试我们对疗效试验的特定方案的预测。为了解决这一挑战性问题,我们提出:(1)确定结核抗生素在肉芽肿中的时空分布,并预测耐药性的发展;(2)使用遗传算法确定结核病的最佳抗生素治疗方案,以缩小抗生素的组合设计空间(例如药物类别、剂量、时间表);(3)在人群水平上进行虚拟临床试验,以测试我们确定的治疗方案,并在NHP系统中对照标准方案测试最佳方案。我们杰出的跨学科团队和独特的方法将允许快速评估新的战略,并最终减少全球结核病死亡人数。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Veronique Dartois其他文献

Veronique Dartois的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Veronique Dartois', 18)}}的其他基金

Pharmacology Core
药理学核心
  • 批准号:
    10513919
  • 财政年份:
    2022
  • 资助金额:
    $ 71.41万
  • 项目类别:
Pharmacology & ImmunoPathology (PIP) Core
药理
  • 批准号:
    10268804
  • 财政年份:
    2021
  • 资助金额:
    $ 71.41万
  • 项目类别:
Pharmacology & ImmunoPathology (PIP) Core
药理
  • 批准号:
    10621303
  • 财政年份:
    2021
  • 资助金额:
    $ 71.41万
  • 项目类别:
Core B: Animal Model Core
核心B:动物模型核心
  • 批准号:
    10190648
  • 财政年份:
    2021
  • 资助金额:
    $ 71.41万
  • 项目类别:
Core B: Animal Model Core
核心B:动物模型核心
  • 批准号:
    10404529
  • 财政年份:
    2021
  • 资助金额:
    $ 71.41万
  • 项目类别:
Core B: Animal Model Core
核心B:动物模型核心
  • 批准号:
    10610918
  • 财政年份:
    2021
  • 资助金额:
    $ 71.41万
  • 项目类别:
Pharmacology & ImmunoPathology (PIP) Core
药理
  • 批准号:
    10430224
  • 财政年份:
    2021
  • 资助金额:
    $ 71.41万
  • 项目类别:
Translational approaches to improve understanding and outcome in Tuberculous meningitis
提高对结核性脑膜炎的理解和结果的转化方法
  • 批准号:
    10007088
  • 财政年份:
    2020
  • 资助金额:
    $ 71.41万
  • 项目类别:
Core C Pharmacology
核心C药理学
  • 批准号:
    10394987
  • 财政年份:
    2019
  • 资助金额:
    $ 71.41万
  • 项目类别:
A Multi-scale systems pharmacology approach to TB therapy
结核病治疗的多尺度系统药理学方法
  • 批准号:
    9762970
  • 财政年份:
    2016
  • 资助金额:
    $ 71.41万
  • 项目类别:

相似海外基金

SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
  • 批准号:
    2213034
  • 财政年份:
    2023
  • 资助金额:
    $ 71.41万
  • 项目类别:
    Cooperative Agreement
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
急诊科的个性化抗生素治疗:PANTHER 试验
  • 批准号:
    10645528
  • 财政年份:
    2023
  • 资助金额:
    $ 71.41万
  • 项目类别:
Strategies for improving the efficacy of combinatorial antibiotic therapy in chronic infections
提高慢性感染联合抗生素治疗疗效的策略
  • 批准号:
    10736285
  • 财政年份:
    2023
  • 资助金额:
    $ 71.41万
  • 项目类别:
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
一种治疗感染性骨折的新型骨靶向抗生素疗法
  • 批准号:
    10603486
  • 财政年份:
    2023
  • 资助金额:
    $ 71.41万
  • 项目类别:
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
  • 批准号:
    449379
  • 财政年份:
    2020
  • 资助金额:
    $ 71.41万
  • 项目类别:
    Studentship Programs
Sex-Specific Differences in End-of-Life Burdensome Interventions and Antibiotic Therapy in Nursing Home Residents With Advanced Dementia
患有晚期痴呆症的疗养院居民的临终干预和抗生素治疗的性别差异
  • 批准号:
    422034
  • 财政年份:
    2020
  • 资助金额:
    $ 71.41万
  • 项目类别:
Optimizing outpatient parenteral antibiotic therapy to support hospital-in-the-home program across the unique environmental conditions of Australia
优化门诊肠外抗生素治疗,以支持澳大利亚独特环境条件下的家庭医院计划
  • 批准号:
    nhmrc : 1197866
  • 财政年份:
    2020
  • 资助金额:
    $ 71.41万
  • 项目类别:
    Investigator Grants
Resistance evolution in the presence of combination antibiotic therapy
联合抗生素治疗下耐药性的演变
  • 批准号:
    2241853
  • 财政年份:
    2019
  • 资助金额:
    $ 71.41万
  • 项目类别:
    Studentship
Host-pathogen interactions in antibiotic therapy for listeriosis
李斯特菌病抗生素治疗中宿主与病原体的相互作用
  • 批准号:
    18K07106
  • 财政年份:
    2018
  • 资助金额:
    $ 71.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones
多用途靶向纳米抗生素疗法可对抗骨骼中的严重感染
  • 批准号:
    9788269
  • 财政年份:
    2018
  • 资助金额:
    $ 71.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了